Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli-Reference-Cited by-同舟云学术

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

Published:2013-12-19 Issue:1 Volume:74 Page:31-51
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Zhanel George G.,Chung Phillip,Adam Heather,Zelenitsky Sheryl,Denisuik Andrew,Schweizer Frank,Lagacé-Wiens Philippe R. S.,Rubinstein Ethan,Gin Alfred S.,Walkty Andrew,Hoban Daryl J.,Lynch Joseph P.,Karlowsky James A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-013-0168-2.pdf

Reference79 articles.

1. Carlet J, Jarlier V, Harbarth S, et al. Ready for a world without antibiotics? The Pensières antibiotic resistance call to action. Antimicrob Resist Infect Control. 2012;1(1):11.

2. Rice LB. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol. 2010;31(Suppl 1):S7–10.

3. Infectious Diseases Society of America. The 10 × ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1081–3.

4. Boucher HW, Talbot GH, Benjamin DK Jr, et al. 10 × ’20 progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–94.

5. Perletti G, Magri V, Wagenlehner FME, et al. CXA-101. Drugs Fut. 2010;35(12):977–86.

Cited by 278 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutations Leading to Ceftolozane/Tazobactam and Imipenem/Cilastatin/Relebactam Resistance Duringin vivoexposure to Ceftazidime/Avibactam inPseudomonas aeruginosa;2024-09-10

2. In vitro activity of ceftolozane/tazobactam against Gram-negative bacilli isolated from pediatric patients: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017–2021, China;Journal of Global Antimicrobial Resistance;2024-09

3. Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam;Antibiotics;2024-08-24

4. Respiratory tract infections: an update on the complexity of bacterial diversity, therapeutic interventions and breakthroughs;Archives of Microbiology;2024-08-17

5. Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012–2021);Heliyon;2024-07